

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Laekna, Inc.**

**來凱醫藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 2105)**

## **VOLUNTARY ANNOUNCEMENT**

### **COMPLETION OF PATIENT ENROLLMENT IN PHASE III CLINICAL TRIAL (AFFIRM-205) OF LAE002 (AFURESERTIB) IN HR+/HER2- LOCALLY ADVANCED OR METASTATIC BREAST CANCER**

This announcement is made by Laekna, Inc. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business update of the Group.

The board (the “**Board**”) of directors of the Company (the “**Directors**”) is pleased to announce that the Group has completed patient enrollment in our phase III clinical trial AFFIRM-205 for LAE002 (afuresertib) plus fulvestrant in patients with PIK3CA/AKT1/PTEN alterations and HR+/HER2- locally advanced or metastatic breast cancer (“**LA/mBC**”) (the “**Phase III Clinical Trial AFFIRM-205**”).

The Phase III Clinical Trial AFFIRM-205 is a multi-center, randomized, double-blind, placebo-controlled pivotal study to assess the anti-tumor efficacy and safety of the combination therapy. The Group targets to readout the topline data of this phase III pivotal study in the first half of 2026, followed by submission of the new drug application to the center for drug evaluation of China’s National Medical Products Administration later in the year. The Group and Qilu Pharmaceutical Company Limited (“**Qilu Pharma**”) have entered into an exclusive licensing agreement (the “**License Agreement**”) on November 12, 2025. Subject to terms and conditions of the License Agreement, Qilu Pharma is granted an exclusive license for research, development, and commercialization of LAE002 (afuresertib) in the China region (including Chinese Mainland, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan). For details, please refer to the announcement of the Company dated November 12, 2025.

## **RISK WARNING**

**LAE002 (AFURESERTIB) MAY NOT ULTIMATELY BE SUCCESSFULLY DEVELOPED AND COMMERCIALIZED. THE COMPANY'S SHAREHOLDERS AND POTENTIAL INVESTORS ARE REMINDED TO EXERCISE CAUTION WHEN DEALING IN THE SECURITIES OF THE COMPANY.**

By Order of the Board  
**Laekna, Inc.**  
**Dr. LU Chris Xiangyang**  
*Chairman*

Hong Kong, December 15, 2025

*As at the date of this announcement, the Board comprises Dr. LU Chris Xiangyang, Ms. XIE Ling and Dr. GU Xiang-Ju Justin as executive Directors; Dr. WANG David Guowei and Mr. SUN Yuan as non-executive Directors; and Dr. YIN Xudong, Dr. LI Min and Mr. ZHOU Jian as independent non-executive Directors.*